Red cells carry almost all the oxygen in blood. When there are too few, or too little haemoglobin, every tissue is short of oxygen and exercise becomes hard. This page explains how red cells are made and controlled, the role of iron, the types of anaemia, and what training and treatment can change.
12Sections
5Figures
3Tables
10Questions
Part 6 · Blood and Immunity · Chapter 26 of 47
Learning objectives
By the end of this page you should be able to:
Describe the structure and lifespan of red cells and the role of haemoglobin.
Explain the erythropoietin feedback loop.
Describe iron absorption, recycling and the role of hepcidin.
Classify anaemia and list common causes.
Explain how anaemia limits exercise and how altitude and iron treatment change red cell status.
Adapt exercise for patients with anaemia.
Why it matters
Anaemia is common in older adults, after surgery, in kidney disease, cancer and heart failure, and in menstruating women and endurance athletes. It causes fatigue and breathlessness and limits rehabilitation.
Knowing the cause tells you what to expect: a patient with iron deficiency may improve with treatment, while a patient with B12 deficiency may also have nerve damage affecting balance.
Red cells and haemoglobin
Red cells are biconcave discs about 7.5 μm across, without a nucleus or mitochondria. Their shape gives a large surface for gas exchange and lets them fold through capillaries narrower than themselves.
Each red cell contains about 270 million haemoglobin molecules. Each haemoglobin has four haem groups, each with an iron atom that binds one oxygen molecule (Chapter 18).
Measure
Typical adult range
Meaning
Haemoglobin
Men about 130–170 g/L; women about 120–150 g/L
Oxygen-carrying protein
Red cell count
About 4.5–6 × 1012/L (men)
Number of cells
Mean cell volume (MCV)
About 80–100 fL
Average cell size
Ferritin
Varies by lab; low values mean low stores
Iron stores (rises in inflammation)
Making red cells
Figure 1 · How red cell production is controlled
A negative feedback loop. Kidney disease reduces EPO, which is why anaemia is common in chronic kidney disease. Altitude switches the loop on [2].
Red cells are made in the bone marrow from stem cells. When the kidney senses low oxygen, it releases erythropoietin (EPO), which speeds production. New red cells appear in the blood after about a week, and they live about 120 days.
Production also needs iron, vitamin B12 and folate. Kidney disease lowers EPO; marrow disease, chemotherapy and nutritional deficiency also reduce output.
Iron
Figure 2 · The iron cycle
Recycling dominates. Daily absorption is small, so losses from bleeding, menstruation or high training loads with raised hepcidin can deplete iron [1].
The body absorbs only a little iron each day and relies on recycling from old red cells. The liver hormone hepcidin controls the flow: it blocks absorption from the gut and release from stores.
Sim and colleagues note that iron deficiency affects about 15–35% of female athlete cohorts and 5–11% of male cohorts [1]. Hepcidin rises for some hours after hard exercise, which can reduce iron absorption [1]. Menstrual losses, low intake and sweat and gut losses add to the risk.
Anaemia
Anaemia is a haemoglobin concentration below the normal range for age and sex. It reduces oxygen content (Chapter 18), so the heart must pump more blood to deliver the same oxygen.
Figure 3 · Classifying anaemia by cell size
Cell size points to the cause. Mean cell volume (MCV) on the blood count is the first clue.
Feature
Explanation
Fatigue, reduced exercise tolerance
Less oxygen delivered to muscle
Breathlessness on exertion
Tissues reach their limit sooner
Fast heart rate, palpitations
Heart raises output to compensate
Pallor
Less haemoglobin in skin vessels
Normal pulse oximetry
Saturation is normal; content is low
Watch out
A pulse oximeter reading of 98% does not rule out a severe shortage of oxygen-carrying capacity. Always check haemoglobin in a patient who is unexpectedly breathless or tired.
Altitude and red cells
Living at altitude lowers arterial oxygen, which raises EPO and red cell production. Levine and Stray-Gundersen sent competitive runners to live at 2,500 m for four weeks [2].
Figure 4 · Altitude raises red cell mass
More haemoglobin, more aerobic capacity. Gains in maximal oxygen uptake tracked the rise in red cell mass [2].
Red cell mass rose about 9% and maximal oxygen uptake about 5% in both altitude groups [2]. Only runners who lived high but trained low improved their 5 km time, because they could keep their training speed [2].
Iron deficiency in heart failure
Iron is needed not only for haemoglobin but also for muscle mitochondria. Anker and colleagues randomised 459 patients with heart failure and iron deficiency to intravenous iron or placebo [3].
Figure 5 · Treating iron deficiency in heart failure
Iron matters even without anaemia. Benefits were similar with and without anaemia, and walking distance and quality of life improved [3].
Intravenous iron improved symptoms, functional class, six-minute walk distance and quality of life, with or without anaemia [3]. Rates of death and adverse events were similar between groups [3].
Practical skill · exercising patients with anaemia
Check the latest haemoglobin and follow local thresholds for activity after surgery or chemotherapy. Start with lower intensity, use rating of perceived exertion and heart rate, and allow longer rests. Stop for chest pain, dizziness or marked breathlessness.
Sim M, Garvican-Lewis LA, Cox GR, et al. Iron considerations for the athlete: a narrative review.European Journal of Applied Physiology. 2019;119(7):1463–1478.
doi:10.1007/s00421-019-04157-yPMID 31055680Review
Levine BD, Stray-Gundersen J. “Living high-training low”: effect of moderate-altitude acclimatization with low-altitude training on performance.Journal of Applied Physiology. 1997;83(1):102–112.
doi:10.1152/jappl.1997.83.1.102PMID 9216951Randomised controlled trial
Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency.New England Journal of Medicine. 2009;361(25):2436–2448.
doi:10.1056/NEJMoa0908355PMID 19920054Randomised controlled trial